LeadIQ logo
Learn more at LeadIQ.com

Insights

Series A Funding EnClear Therapies secured $10 million in Series A financing, highlighting investor confidence and potential for accelerated growth.

Innovative Medical Device EnClear's development of a semi-permanent, pump-sized device for filtering toxic proteins from cerebral spinal fluid presents a unique sales opportunity in the medical equipment market.

Key Leadership Recruitment Hiring Kevin Kalish as Vice President of Research and Development signifies EnClear's commitment to top talent, creating opportunities for strategic collaborations and market positioning.

Cutting-Edge Therapeutic Systems EnClear's focus on developing systems to clear toxic proteins from cerebrospinal fluids showcases potential partnerships with healthcare providers seeking innovative treatment solutions.

Target Market Alignment With a sustainability focus on improving patient lives in CNS disease treatment, EnClear aligns well with a market seeking impactful medical interventions, offering a compelling sales narrative.

Similar companies to EnClear Therapies

EnClear Therapies Tech Stack

EnClear Therapies uses 8 technology products and services including Google Cloud, RequireJS, React, and more. Explore EnClear Therapies's tech stack below.

  • Google Cloud
    Infrastructure As A Service
  • RequireJS
    Javascript Frameworks
  • React
    Javascript Frameworks
  • Zepto
    Javascript Libraries
  • Lodash
    Javascript Libraries
  • Polyfill
    Javascript Libraries
  • reCAPTCHA
    Security
  • Bootstrap
    UI Frameworks

Media & News

EnClear Therapies's Email Address Formats

EnClear Therapies uses at least 1 format(s):
EnClear Therapies Email FormatsExamplePercentage
F.Last@encleartherapies.comJ.Doe@encleartherapies.com
41%
Last@encleartherapies.comDoe@encleartherapies.com
9%
F.Last@encleartherapies.comJ.Doe@encleartherapies.com
41%
Last@encleartherapies.comDoe@encleartherapies.com
9%

Frequently Asked Questions

Where is EnClear Therapies's headquarters located?

Minus sign iconPlus sign icon
EnClear Therapies's main headquarters is located at 65 Park St 3 Newburyport, Massachusetts 01950 US. The company has employees across 1 continents, including North America.

What is EnClear Therapies's official website and social media links?

Minus sign iconPlus sign icon
EnClear Therapies's official website is encleartherapies.com and has social profiles on LinkedIn.

How much revenue does EnClear Therapies generate?

Minus sign iconPlus sign icon
As of October 2024, EnClear Therapies's annual revenue reached $750K.

What is EnClear Therapies's NAICS code?

Minus sign iconPlus sign icon
EnClear Therapies's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does EnClear Therapies have currently?

Minus sign iconPlus sign icon
As of October 2024, EnClear Therapies has approximately 12 employees across 1 continents, including North America. Key team members include Chief Business Officer: D. H.Chief Operating Officer: K. K.Vice President Biology: M. G.. Explore EnClear Therapies's employee directory with LeadIQ.

What industry does EnClear Therapies belong to?

Minus sign iconPlus sign icon
EnClear Therapies operates in the Medical Equipment Manufacturing industry.

What technology does EnClear Therapies use?

Minus sign iconPlus sign icon
EnClear Therapies's tech stack includes Google CloudRequireJSReactZeptoLodashPolyfillreCAPTCHABootstrap.

What is EnClear Therapies's email format?

Minus sign iconPlus sign icon
EnClear Therapies's email format typically follows the pattern of . Find more EnClear Therapies email formats with LeadIQ.

When was EnClear Therapies founded?

Minus sign iconPlus sign icon
EnClear Therapies was founded in 2018.
EnClear Therapies

EnClear Therapies

Medical Equipment ManufacturingMassachusetts, United States11-50 Employees

At EnClear Therapies, we are combining Bioscience & Med-tech expertise to develop solutions that improve and extend the lives of patients with CNS disease.

The team at EnClear is developing systems and medical interventions that Access, Recirculate & Modify CSF for:
›	Targeted removal of toxicity from CSF correlated to neurodegenerative disease progression.
›	Continuous localized delivery of therapeutics & monitoring of CSF to ensure effective and personalized therapy.

Section iconCompany Overview

Headquarters
65 Park St 3 Newburyport, Massachusetts 01950 US
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $10M

    EnClear Therapies's revenue is in the range of $10M

Section iconFunding & Financials

  • $10M

    EnClear Therapies's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.